A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Chen, Qi ^a   Prior, Marguerite ^a   Dargusch, Richard ^a   Roberts, Amanda ^c   Riek, Roland ^a,d   Eichmann, Cédric ^d   Chiruta, Chandramouli ^a   Akaishi, Tatsuhiro ^b   Abe, Kazuho ^b   Maher, Pamela ^a   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b MUSASHINO UNIVERSITY   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CNB 001; CNB 023; GALANTAMINE; GLUTATHIONE; HEAT SHOCK PROTEIN; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; J 147; NEUROPROTECTIVE AGENT; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CURCUMIN; DRUG DERIVATIVE; NERVE GROWTH FACTOR; OXIDIZING AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; GLUTATHIONE METABOLISM; INFLAMMATION; LONG TERM POTENTIATION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECT; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; MEMORY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SOLUBILITY; SYNAPSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; CURCUMIN; DISEASE MODELS, ANIMAL; HEAT-SHOCK PROTEINS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LONG-TERM POTENTIATION; MEMORY; MICE; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATIVE STRESS; PHOSPHORYLATION; PYRAZOLES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPSES; UP-REGULATION;

EID: 83355173051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027865     Document Type: Article

References (84)

1. Pangalos MN, Schechter LE, Hurko O, (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 521-532.
2. Herrup K, (2010) Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 30: 16755-16762.
3. Frautschy SA, Cole GM, (2010) Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 41: 392-409.
4. Ganesan A, (2008) The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 12: 306-317.
5. Cole GM, Teter B, Frautschy SA, (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595: 197-212.
6. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377.
7. Schubert DR, Liu Y, (2002) Method for preventing and/or decreasing amyloid production with polycyclic compounds. US Patent No. 6,472,436B1 US Patent No 6,472,436B1.
8. Liu Y, Dargusch R, Maher P, Schubert D, (2008) A broadly neuroprotective derivative of curcumin. J Neurochem 105 1336-1345.
9. Haigis MC, Yankner BA, (2010) The aging stress response. Mol Cell 40: 333-344.
10. Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD, (2009) Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem 57: 83-89.
11. Abe K, Takayanagi M, Saito H, (1990) Effects of recombinant human basic FGF and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Japan J Pharmacol 53: 221-227.
12. Tan S, Schubert D, Maher P, (2001) Oxytosis: A novel form of programmed cell death. Curr Topics Med Chem 1: 497-506.
13. Yankner BA, Duffy LK, Kirschner DA, (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250: 279-282.
14. Pajouhesh H, Lenz GR, (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2: 541-553.
15. Rossler OG, Giehl KM, Thiel G, (2004) Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. J Neurochem 88: 1240-1252.
16. Maher P, (2010) Modulation of multiple pathways involved in the maintenance of neuronal function by fisetin. In: Parker L, Sies H, Eggersdorfer M, Cardenas E, editors. Micronutrients and Brain Health Boca Raton, FL CRC Press pp. 189-206.
17. Winkler BS, Sauer MW, Starnes CA, (2003) Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms. Exp Eye Res 76: 715-723.
18. Maher P, Salgado KF, Zivin JA, Lapchak PA, (2007) A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173: 117-125.
19. Chen J, Zacharek A, Zhang C, Jiang H, Li Y, et al. (2005) Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci 25: 2366-2375.
20. Olin D, MacMurray J, Comings DE, (2005) Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci Lett 381: 275-278.
21. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S, (2008) New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 59: 201-220.
22. Pezet S, Malcangio M, (2004) Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 8: 391-399.
23. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, et al. (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76: 280-286.
24. Ennaceur A, Delacour J, (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59.
25. Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, et al. (2005) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 179: 613-619.
26. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL, (2001) Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A 98: 2089-2094.
27. Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, et al. (2000) Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A 97: 14731-14736.
28. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA, (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122: 150-202.
29. Bach ME, Hawkins RD, Osman M, Kandel ER, Mayford M, (1995) Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. Cell 81: 905-915.
30. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, et al. (2005) Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 25: 5217-5224.
31. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617.
32. van Groen T, Kiliaan AJ, Kadish I, (2006) Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23: 653-662.
33. Lalonde R, Kim HD, Maxwell JA, Fukuchi K, (2005) Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 390: 87-92.
34. Vorhees CV, Williams MT, (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
35. Wang F, Chen H, Sun X, (2009) Age-related spatial cognitive impairment is correlated with a decrease in ChAT in the cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci Lett 454: 212-217.
36. Harrison FE, Hosseini AH, McDonald MP, May JM, (2009) Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol Biochem Behav 93: 443-450.
37. Krafft GA, Klein WL, (2010) ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology 59: 230-242.
38. Bishop NA, Lu T, Yankner BA, (2010) Neural mechanisms of ageing and cognitive decline. Nature 464: 529-535.
39. Cameron B, Landreth GE, (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37: 503-509.
40. Dore S, (2002) Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer's disease. Free Radic Biol Med 32: 1276-1282.
41. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D, (2009) Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 110: 469-485.
42. Radmark O, Werz O, Steinhilber D, Samuelsson B, (2007) 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341.
43. Phillis JW, Horrocks LA, Farooqui AA, (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52: 201-243.
44. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, et al. (2010) Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333: 72-81.
45. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, et al. (2005) Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis 7: 103-117; discussion 173-180.
46. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9: 234-242.
47. Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, et al. (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90: 1-13.
48. Cunha C, Brambilla R, Thomas KL, (2010) A simple role for BDNF in learning and memory? Front Mol Neurosci 3: 1.
49. Sato M, Suzuki K, Nakanishi S, (2001) NMDA receptor stimulation and brain-derived neurotrophic factor upregulate homer 1a mRNA via the mitogen-activated protein kinase cascade in cultured cerebellar granule cells. J Neurosci 21: 3797-3805.
50. Yoshimura Y, Shinkawa T, Taoka M, Kobayashi K, Isobe T, et al. (2002) Identification of protein substrates of Ca(2+)/calmodulin-dependent protein kinase II in the postsynaptic density by protein sequencing and mass spectrometry. Biochem Biophys Res Commun 290: 948-954.
51. Guerreiro RJ, Gustafson DR, Hardy J, (2010) The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 2010 Jun 2029 Epub ahead of print.
52. Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B, (1996) Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381: 706-709.
53. Allen GL, Kirasic KC, Rashotte MA, Haun DB, (2004) Aging and path integration skill: kinesthetic and vestibular contributions to wayfinding. Percept Psychophys 66: 170-179.
54. Bach ME, Barad M, Son H, Zhuo M, Lu YF, et al. (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96: 5280-5285.
55. Barnes CA, (1979) Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol 93: 74-104.
56. Aggleton JP, Hunt PR, Rawlins JN, (1986) The effects of hippocampal lesions upon spatial and non-spatial tests of working memory. Behav Brain Res 19: 133-146.
57. Morris RG, Garrud P, Rawlins JN, O'Keefe J, (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-683.
58. Broadbent NJ, Gaskin S, Squire LR, Clark RE, (2010) Object recognition memory and the rodent hippocampus. Learn Mem 17: 5-11.
59. Lanni C, Lenzken SC, Pascale A, Del Vecchio I, Racchi M, et al. (2008) Cognition enhancers between treating and doping the mind. Pharmacol Res 57: 196-213.
60. Minichiello L, (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10: 850-860.
61. Dugich-Djordjevic MM, Peterson C, Isono F, Ohsawa F, Widmer HR, et al. (1995) Immunohistochemical visualization of brain-derived neurotrophic factor in the rat brain. Eur J Neurosci 7: 1831-1839.
62. Berchtold NC, Castello N, Cotman CW, (2010) Exercise and time-dependent benefits to learning and memory. Neuroscience 167: 588-597.
63. Griesbach GS, Hovda DA, Gomez-Pinilla F, (2009) Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation. Brain Res 1288: 105-115.
64. Radak Z, Hart N, Sarga L, Koltai E, Atalay M, et al. (2010) Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis 20: 777-783.
65. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, et al. (2004) Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 101: 10827-10832.
66. Gorski JA, Balogh SA, Wehner JM, Jones KR, (2003) Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121: 341-354.
67. Engert F, Bonhoeffer T, (1999) Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399: 66-70.
68. Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, et al. (1996) Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 25: 821-828.
69. Dun XP, Chilton JK, (2010) Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin. Histol Histopathol 25: 533-540.
70. Yamagata Y, (2003) New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J Pharmacol Sci 93: 22-29.
71. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, et al. (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59: 290-294.
72. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, et al. (2009) Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23: 2459-2466.
73. Orozco-Ibarra M, Chirino YI, Pedraza-Chaverri J, (2006) Role of hemeoxygenase-1 in the neurodegenerative disorders. Rev Neurol 43: 556-562.
74. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D, (2005) Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58: 623-626.
75. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST, (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 56: 1065-1073.
76. Wollen KA, (2010) Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev 15: 223-244.
77. Zahs KR, Ashe KH, (2010) 'Too much good news'- are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 33: 381-389.
78. Coma M, Sereno L, Da Rocha-Souto B, Scotton TC, Espana J, et al. (2010) Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 38: 482-491.
79. Golde TE, Schneider LS, Koo EH, (2011) Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203-213.
80. Behl C, Davis JB, Lesley R, Schubert D, (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827.
81. Abe K, Kimura H, (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071.
82. Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, et al. (2003) A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 100: 10518-10522.
83. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, et al. (2007) Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 282: 22707-22720.
84. Lapchak PA, Schubert DR, Maher PA, (2011) Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ichemic stroke. J Neurochem 116: 122-131.